CBD Forum by Chow420

Go back
Refer
$20
Refer
Get $20 in Chowcash when you refer friends, stores, and brands to Chow420. Your friends also get $20 towards their first purchase when they accept your invitation.
Login to Refer

Hemp News, Laws & Product Updates

A curated news hub focused on hemp regulation and policy changes, cannabinoids (CBD/Delta-8/Delta-9/hemp-derived THC), lab testing and COAs, product safety, brands, and industry trends.

  • Federal & State Hemp Laws
  • THC Policy
  • CBD / Delta-8
  • Compliance
  • Lab Testing (COA)
  • Product Safety
  • Industry & Brands
Back to Chow420
https://hightimes.com/

First Black, Woman-Owned Psilocybin Treatment Center Opens

A woman and minority-owned psilocybin treatment center in Oregon, the first of its kind, will soon open doors. It was co-founded by a mother and daughter team, Denise Taylor, a registered nurse (RN), and Laurie Thompson, an experienced meditator. Ashland Healing Center will provide relief to patrons for mental health conditions, PTSD, anxiety, depression, addiction, and end-of-life concerns, according to a May 21 announcement. During the journey each client is supported by a licensed Psilocybin Facilitator, and the focus is on psilocybin for personal transformation.  With the guidance of an experienced Psilocybin Facilitator, patrons are able to avoid unpleasant effects of the mushroom and its derivatives. “We partner with healthcare professionals to get the best results for our mutual clients and patients. Our services are of special interest to medical professionals, therapists, counselors, integrative health care practitioners, and anyone interested in improving mental health. We offer complimentary consultations to those interested in our services. We are also the only black-owned legal Psilocybin service center and are committed to improving mental health outcomes for the black community,” said Taylor. Taylor’s expertise as an RN helps the team to make better choices about potential interactions and safety issues. Psilocybin sessions go as follows, in four steps: The Oregon Psilocybin Advisory Board approved a limited number of recommendations. But Ashland Healing Center co-founders say that studies from John Hopkins, UC Davis, Yale, and NYU have demonstrated a broader span of potential for psilocybin-assisted therapy. “Psilocybin provides both medical and metaphysical/spiritual benefits,” said Thompson. “The results our clients experience are incredible. I’ve witnessed depression becoming love, relief from migraine headaches, spiritual experiences, release of intergenerational trauma, and physical healing. We are honored to offer these services and have served clients from across the nation. Ashland, Oregon, is accessible via the Rogue Valley International Medford Airport (code MFR).” As the direction of psilocybin sessions heavily relies on an individuals’ set and setting, much of the experience is self-directed. “Psilocybin treatment is not therapy,” the website states. “It is self-directed. Although success is often received with just one treatment, your intent and desire to change are of paramount importance. A willingness to begin working on that change before the experience and to continue after are key to your continued success. Safety and comfort are also important. We want you to work with a facilitator you trust in a safe place. As facilitators we will work with you to build trust.” In November 2020, Oregon voters  approved Measure 110, and the state officially became the first e to decriminalize hard drugs such as heroin or methamphetamine, and also legalized the use of psilocybin mushrooms for therapeutic use. By December 2022, the state was training facilitators to care for participants experiencing their psilocybin journey. It took until May 2023 to approve the first license, which belonged to EPIC Healing Eugene. A consult, which is free, typically lasts one hour. Beginning with Denver, Colorado, the first city to decriminalize psilocybin in 2019, other cities followed including Oakland and Santa Cruz, California; Washington, D.C.; Somerville, Cambridge and Northampton, Massachusetts; Seattle, Washington; and Detroit, Michigan. Oregon and Colorado moved to decriminalize psilocybin at the state level as well. Psilocybin is being explored for its role in helping people with eating disorders (ED), treatment-resistant depression and post-traumatic stress disorder (PTSD), and even stress due to childhood trauma. Psilocybin’s effects on ED, for instance, have been explored since the 1950s, and studies are zeroing in its ability to help us overcome treatment-resistant conditions like body dysmorphia, anorexia, or bulimia. Researchers Elena Koning and Elisa Brietzke are exploring the ways psilocybin can treat ED by its therapeutic benefits in combating rigid thought patterns. Koning, who is a doctoral student, recently wrote about her discoveries for PsyPost, explaining the reasoning behind her research. Koning mentioned that in the age of social media, EDs are becoming increasingly troublesome, and that new approaches to those types of disorders are needed. A recent study, “Psilocybin-Assisted Psychotherapy as a Potential Treatment for Eating Disorders: a Narrative Review of Preliminary Evidence,” was published online ahead of print for Trends Psychiatry. Another recent study, published recently in the Journal of Psychoactive Drugs, took a closer look at adverse childhood experiences as an “elevated risk for psychological distress,” specifically looking at how psilocybin may abate these effects. It was authored by researchers at Simon Fraser University, Athabasca University, University of British Columbia and University of Michigan. Researchers found that the use of psilocybin can help to ease psychological distress in people who had adverse experiences as children, indicating that psilocybin appeared to hold “particularly strong benefits to those with more severe childhood adversity.”

https://hightimes.com/

Travel on High

When you hear the phrase “cannabis tourism,” what comes to mind? A party bus with smoke billowing out of open windows? Scaling the side of a grassy hill to get a glimpse of the cannabis promised land? Perhaps hitting a joint and then gently descending into a child’s pose? All of these are correct. Cannabis-related tourism has evolved quite a bit since the early days of legalization. When Colorado voters passed adult use in 2012, people from all over the country flocked to the Centennial State to experience something they never had before—consuming cannabis legally. Early cannabis tourism experiences experimented with ideas, which commonly consisted of taking patrons to dispensaries where they could shop and then providing a safe space for them to consume their purchases, which was usually inside a tour bus or an outside venue. This brand of tourism exists in other markets as well, such as the craft beer market. People sign up for pub crawls where attendees can sample and purchase unique brews. Craft beer tourism also includes dinners with menus to highlight the flavors of the hops, tours of breweries where the beer is being made, as well as art gallery and music events where local, craft beers are showcased. There are even athletic events like Beer Mile, which incorporates both running and beer consumption in competition. So, what does that mean for the future of cannabis tourism? Certain regions in California are known for their wine culture. Napa, Sonoma, and Santa Barbara counties draw millions of people annually who enjoy leisurely strolls through the vineyards, artisan cheeses, and world-renowned wine. It’s a whole lifestyle. Similarly, Kentucky draws bourbon aficionados seeking the finest aged liquor. While still in its infancy, the cannabis sector of tourism has immense potential. The famed Emerald Triangle of northern California, including Mendocino, Humboldt, and Trinity counties, has a storied and rich history of cannabis cultivation and culture going back decades. Much of the production and cultivation of high-quality cannabis, as seen with today’s most popular strains, took place in those hills. While the stringent framework of cannabis legalization and the opinion of some who believe that cannabis grown outdoors is inferior (as if!) has taken its toll on the economic viability of production in this region, the history and stories are unmatched. Furthermore, the craft, legacy genetics, and regenerative cultivation techniques applied by farmers in the Emerald Triangle produce cannabinoid and terpene profiles that are complex, therapeutic, and unique to the region. (Here’s a tip: the next time you visit your local California dispensary, ask for something grown outdoors in the Emerald Triangle. You’re welcome.) Farm tours, farmers’ markets, and cannabis farm-to-table style dinners are just some of the offerings that could be featured in cannabis tourism. However, regulatory barriers like not allowing farmers to sell directly to the consumer or making it difficult to establish a tasting room in the small towns that dot Highway 101 have limited the realization of culture-driven cannabis tourism. Cannabis yoga was one of the first wellness activities to overtly pair wellness with consumption. Truthfully, many of us have been getting high before experiencing yoga, massages, meditation, and painting for as long as we can remember. However, the concept of marketing these activities with cannabis only surfaced after legalization. While the places where people can publicly smoke cannabis are limited, even in legal states, opportunities to openly consume at private facilities like yoga studios or outdoor venues make them a popular choice among the wellness crowd. As the normalization of cannabis use continues, these offerings may be less in the camp of cannabis tourism and more under the umbrella of wellness in general. Pairing and integrating cannabis with food is a perfect match, even when many of us, while in the throes of the munchies, have made some suspect food pairing decisions.  I recall one particular night when I was convinced that the peanut butter and easy cheese sandwich I had made was a culinary marvel. Still the fact remains that cannabis has the potential to enhance not only our appetites but also the experience of eating. Furthermore, like pairing food with wine, the flavors and aromas in cannabis can complement food as well, elevating both the cannabis, the meal, and you! There are two main types of cannabis dinners. The first pairs food with specific strains of cannabis to compliment the flavors and aromas of both and to guide the consumer through the meal in the context of the effects of cannabis. The second infuses meals with THC or other cannabinoids, which puts the focus on a high that evolves throughout the experience. This type of cannabis tourism is very popular among consumers. In the 2023 Consumer Survey from New Frontier Data, 73% of respondents said they would like to attend an infused dinner. Cannabis tourism once focused squarely on giving people who live in illegal states the chance to buy and consume cannabis without fear. As more states have continued to change their laws and more people have access to legal products, not only in their state but also in the neighboring ones, the offerings have shifted to include cannabis as a component of another activity, including cannabis in the context of dining as well as opportunities to experience and learn about legacy cannabis culture. There are many more emerging opportunities in the cannabis tourism space. To learn more about what’s trending, check out the Cannabis Travel Association International at cannabistravelassociation.org. This article was originally published in the March 2024 issue of High Times Magazine.

https://hightimes.com/

Quit Meth, Get Paid in Innovative California Recovery Program

A new California program incentivizes people using meth or cocaine with money if they can prove they are clean in an evidence-based system in which participants can earn incrementally more the longer they stay clean. Why? Because California is grappling with substance use disorder “crisis” with deaths from cocaine, meth, and other stimulants soaring in recent years. In 2021 for instance, 65% of drug-related overdose deaths involved stimulants, compared to 22% in 2011. The impulsive nature of stimulant cravings and addiction calls for alternative approaches. A Medi-Cal initiative called CalAIM provides social and behavioral health services, including addiction treatment to individuals in California . California Healthline reports that CalAIM provides people who use meth and cocaine with an incentive to quit habit-forming drugs that are difficult to kick on your own. Contingency Management (CM) is a program that provides motivational incentives to treat people who use stimulants like meth or cocaine, and support their path to recovery. It recognizes and reinforces individual positive behavioral change, and requires them to prove it with drug tests showing negative results for stimulants. “CM is the only treatment that has demonstrated robust outcomes for individuals living with stimulant use disorder, including reduction or cessation of drug use and longer retention in treatment,” the program states. “The Recovery Incentives Program increases access to new evidence-based treatments for Californians living with substance use disorder,” the program’s Fact Sheet states. “Starting in 2023, the program is available to members living with stimulant use disorder in participating counties, in outpatient, intensive outpatient, and Narcotic Treatment Program settings. As part of the program, eligible Medi-Cal members participate in a structured 24-week outpatient program, followed by at least six months of additional recovery support services. Participants meet with a trained contingency management coordinator twice weekly for the first 12 weeks of the program, then weekly for weeks 13 to 24 to complete a drug test. Participants receive a small gift card each time they test negative for stimulants and can earn up to $599 per year in incentives.” California is the first state in the country to receive federal approval of CM as a benefit in the Medicaid program through the CalAIM 1115 Demonstration. CM also tested other sources of funding. According to the state Department of Health Care Services, about 2,700 patients from 19 counties have enrolled in the program since April 2023. Quinn Coburn, 65, who is in the program, told California Healthline, “It’s that little something that’s holding me accountable.”  Coburn received $10 for each clean urine test he provided the first week of the program, and the pay increases in subsequent weeks: $11.50 per test in week two, $13 in week three—up to $26.50 per test. The program promises as much as $599 a year, and Coburn is proof that it’s doable: As of mid-May, Coburn had completed 20 weeks of clean drug tests and made $521.50. “The way stimulants work on the brain is different than how opiates or alcohol works on the brain,” said John Duff, lead program director at Common Goals, where Coburn receives treatment. “The reward system in the brain is more activated with amphetamine users, so getting $10 or $20 at a time is more enticing than sitting in group therapy.”. The average recovery rate for people suffering from meth addiction is around 37%, which is about equal to other physically addictive drugs such as cocaine, heroin, and prescription drugs. Cannabis is also being explored as a potential treatment to help reduce stimulant cravings. The fight against meth abuse is also taking place at the national level. In 2022, President Joe Biden signed legislation designed to address the rising scourge of meth abuse in the United States. The new law, titled the Methamphetamine Response Act, “requires the government to declare methamphetamine an ‘emerging drug threat’ and to develop a response plan specific to methamphetamine,” according to a press release. The bill had bipartisan support in the House of Representatives and Senate: its sponsors were Sens. Dianne Feinstein (D-Calif.) and Chuck Grassley (R-Iowa) and Reps. Scott Peters (D-Calif.) and John Curtis (R-Utah). According to a study from the National Institutes of Health, “overdose deaths involving methamphetamine nearly tripled from 2015 to 2019 among people ages 18-64 in the United States.” That study showed that the “number of people who reported using methamphetamine during this time did not increase as steeply, but the analysis found that populations with methamphetamine use disorder have become more diverse,” suggesting that “increases in higher-risk patterns of methamphetamine use, such as increases in methamphetamine use disorder, frequent use, and use of other drugs at the same time, may be contributing to the rise in overdose deaths.”

https://hightimes.com/

Study To Determine Impact of Cannabis on Driving Ability Delayed

An Australian trial that will investigate the impact of medical cannabis on driving ability won’t be finished until late 2025. The Guardian reports that Australian cannabis advocates are disappointed that the Victorian government appears to be delaying the study despite the issue being called a priority. In February 2023, then-state premier Daniel Andrews pushed to determine how cannabis impacts driving ability and said that the issue is a priority for the Victornian government. He estimated as many as 200,000 medicinal cannabis patients in Victoria are essentially restricted from driving.  That’s because THC can be detected in the body for weeks, if not months after consumption, meaning medicinal cannabis patients can essentially never drive without worry of driving while what authorities consider to be impaired. Victorian premier Jacinta Allan announced May 14 that Swinburne University of Technology in Melbourne, Australia has been selected to run the trial. The $4.9 million dollar trial ($3.26 million USD), to be completed over 18 months , will review about 70 medicinal cannabis patients’ ability to manage distractions and assess their performance behind the wheel, including steering, braking, and speed control on a dedicated track. “Just as we were the first state in the nation to introduce medicinal cannabis to support people with their medical illnesses, we are now moving to have this world-first trial to support and examine how it affects people as they’re out on this closed circuit driving track,” Allan said. Victoria became the first Australian state to legalize medical cannabis in 2016, but it remains illegal for individuals to drive with any trace of THC in their bloodstream. Legalise Cannabis MPs David Ettershank and Rachel Payne said they were disappointed in the timeline. “Jacinta Allan may be on a driving track today but I know she is intentionally ‘stalling’ on this decision,” Payne said. “In 2023, Dan Andrews promised an answer ‘in coming months’ followed by a guarantee to have it fixed by 2024. Now, with a new premier, it’s mid-2026 at best.” Ettershank suggested was “discriminating” against medicinal cannabis patients and the motives were political. What could change? Already in Tasmania, leaders established a medical defense if drivers are caught behind the wheel with THC in their system, as it can linger there for weeks or months. But roads minister, Melissa Horne said Tasmania had far fewer medicinal cannabis patients than Victoria. “At the heart of it, it is a basic human rights issue where we’ve got people out there who are taking a legally prescribed substance who cannot drive at the moment,” she said. While cannabis breathalyzers have emerged, made by several companies, there is currently very few, if any places in the world that has developed standardized cannabis impairment testing; All that exists are tests that can detect THC in the bloodstream, but that has little to do with current impairment. That could change quickly, however. Researchers in Australia have been determining the window that cannabis can impair driving performance. In one case, Thomas R Arkell, Danielle McCartney , Iain S McGregor, who are associated with The Lambert Initiative at the University of Sydney, studied the impact of cannabis on driving ability. They determined that cannabis can impair driving ability in the hours immediately after smoking, but the impairment ends well before THC metabolites are flushed from the bloodstream. “Patients using THC-containing products should avoid driving and other safety-sensitive tasks (e.g. operating machinery), particularly during initiation of treatment and in the hours immediately following each dose,” the authors wrote. “Patients may test positive for THC even if they do not feel impaired, and medical cannabis use does not currently exempt patients from mobile (roadside) drug testing and associated legal sanctions.” Hound Labs, based in Oakland, California, said in 2021 that market release is imminent for its Hound Marijuana Breathalyzer, which can detect the presence of THC molecules in the breath. “The first commercial units of the Hound Marijuana Breathalyzer will be in the hands of customers this spring,” Dr. Mike Lynn, an emergency room physician who is CEO and co-founder of Hound Labs, told High Times. “Production will ramp up throughout the rest of 2021.” The introduction of the Hound Breathalyzer could really shake things up for law enforcement, motorists, employees, employers, and medical cannabis patients. It’s different from other drug tests because Hound Labs reps say it can test whether the person is currently high, as measured by the presence of THC molecules in the breath. The developers of the Hound believe that THC molecules linger in the breath for up to four hours after smoking.  In the U.S., 12 states—Arizona, Delaware, Georgia, Indiana, Iowa, Michigan, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Utah and Wisconsin—have zero-tolerance laws for certain drugs including THC.

https://hightimes.com/

Delaware Bill Would Allow Medical Cannabis Operators To Sell Adult-Use Cannabis

In Delaware, a new bill is being proposed to allow medical cannabis businesses to also sell adult-use cannabis once the state’s adult-use sales begin. House Bill 408 was recently introduced on May 16 by sponsors Rep. Ed Osienski and Sen. Trey Paradee. Delaware’s Marijuana Control Act was enacted on April 27, 2023 without the signature of Gov. John Carney, and went into effect starting on August 1, 2023. It created four different license types but none of which currently permit medical cannabis compassion centers to take part in the upcoming launch of adult-use sales. If passed, HB-408 would create a temporary conversion license that medical cannabis businesses can apply for in order to sell adult-use cannabis, and if the application is approved, the license would expire after four years have passed, and can then be renewed again. “As Delaware moves closer to the launch of recreational marijuana sales, it’s important that we continue exploring and implementing policies that will bolster the program’s success and support both new and existing retailers,” Osienski said in a press release. “Our experienced compassion centers are well-equipped to navigate this transition, and the funds generated from their conversion license fees will serve as a vital funding source for social equity applicants, empowering them to kickstart their ventures.” According to HB-408, the medical cannabis business must currently be eligible for renewal within the medical program, must be able to show that it can meet market demands (in addition to verify its plans for continued service in medical cannabis and show support for the social equity program), and have a signed labor peace agreement with a labor organization. Applicants must also pay the fee for a conversion license, which is currently set at $100,000 per license. The proceeds from the fee will be used to give financial assistance to conditional license holders who are also social equity applicants. “For us, passing the Marijuana Control Act was always about our desire to replace an illegal market that has overwhelmed our court system and damaged lives with a legal, regulated and responsible industry that will create thousands of good-paying jobs in Delaware,” Paradee said. “We also need to protect the jobs created by our compassion centers, who have already put in the hard work of standing up an industry and have the capacity and infrastructure to meet demand on Day 1.” Paradee added that providing an avenue for medical cannabis businesses to participate in the adult-use market will aid communities harmed by the War on Drugs. If HB-408 became law, it would require that the Delaware Office of the Marijuana Commissioner open up applications between August 1-November 1, 2024. For now, it heads to the House Economic Development/Banking/Insurance and Commerce Committee. Earlier this year, Osienski introduced another bill, House Bill 285, which aims to expand the Delaware medical cannabis program. Medical cannabis was first legalized in Delaware in 2011 but sales didn’t begin until 2015 when the first dispensary began operation. If passed, HB-285 would allow senior citizens to become medical cannabis patients, permit healthcare providers to determine whether or not medical cannabis could be useful for a patient, and improve the cannabis registry ID card process. “With the full legalization of adult-use recreational marijuana last year, my colleagues and I agreed that our medical marijuana law needed to be updated to help the people who rely on those products get the therapy they need,” said Sen. Kyra Hoffner, according to WBOC. “These changes will allow healthcare providers to make sound decisions about which treatments best fit their patients, and make those treatments more readily accessible to people who need them the most. I want to thank my colleagues in the General Assembly for continuing to support a responsible and reasoned approach to both recreational and medical marijuana in the First State.” HB-285 is currently waiting on Gov. Carney’s desk for a signature or veto. In April, Osienski and Paradee, in addition to state treasurer Colleen Davis, filed House Bill 355, which would implement state protections for banks who seek to serve licensed cannabis businesses.  This would apply to banks as well as “credit unions, armored car services, and providers of accounting services” which wouldn’t be subject to prosecution under Delaware state law. “This is really a public safety issue,” said Paradee last month. “We do not want any of the current medical cannabis providers or the coming recreational cannabis providers to struggle with that issue.” While these bills await their respective approvals, many eagerly await the news of when adult-use cannabis sales will begin. While an official date has not yet been verified, the most recent launch estimate is currently looking toward March 2025, according to Delaware Marijuana Commissioner Robert Coupe told the Joint Finance Committee in February. In the meantime, a slew of other bills recently headed to Gov. Carney’s desk for approval, such as House Substitute 1 for House Bill 162, which would legalize human composting. If approved, it would allow licensed morticians to care for the deceased as they decompose by mixing the bodies with wood chips, straw, and other organic materials. After fully decomposed (estimated to take approximately 30 days), the compost would be returned to the family to use as they see fit.

https://hightimes.com/

Iowa Governor Signs Bill To Regulate Hemp Products

On May 17, Iowa Gov. Kim Reynolds signed 20 bills prior to the end of the legislative session. One of which was House File 2605, which establishes regulations regarding hemp-derived consumable products that contain THC. The passage of HF-2605 includes new restrictions and penalties applied for hemp-derived consumable sales, manufacturing, and possession. Now, such products may only contain 4 mg of THC per serving, or 10 mg THC per container on a dry weight basis, according to the Iowa Capital Dispatch. It also requires that warning labels be adhered to those products, which can be sold to adults over 21, and prohibits the use of synthetic THC. Many people reached out expressing their opposition to the bill, and called for Reynolds to reject it. Prior to signing HF-2605, Reynolds explained that she considered both sides of the argument for and against the bill. “I have concerns about this bill and have heard from individuals and groups on both sides of the issue,” said Reynolds. “Ultimately, I am signing it into law to protect minors from dangerous and intoxicating products. At the same time, we’ve taken steps to ensure that children who are resistant to medications and suffer from seizures and other medical conditions continue to have access to consumable hemp alternatives for relief.” In early April, HF-2605’s floor manager, Sen. Dan Dawson, explained that the bill is a necessary update to the Iowa Hemp Act. “The medical cannabidiol program actually puts an individual with a doctor to get these products, that’s the biggest distinction,” Dawson said. “The Iowa hemp program has none of those barriers there. So if we want to protect Iowans with these products… there has to be some type of guardrails on here, to make sure that the medical cannabidiol program is the program that we can direct Iowans to when they have one of these diagnosed conditions.” In March, Rep. John Forbes expressed concern for the possible “unintended consequences” for patients who rely on hemp-based medicine that’s not included in the state medical cannabis program. “I think we’re not hitting the nail on the head here, when it comes to being able to help Iowans that are seeking out this as an alternative to maybe taking other prescription medications, and increasing quality of life, helping them,” Forbes said at the time. During that same meeting, Sen. Tom Shipley, who helped create the Iowa Hemp Act when it passed in 2019, said he saw opportunities for loopholes. However, he was more than happy to support HF-2605 as a way to improve upon the current act. “We found out some people could find an angle to get around things and do things that are not good for Iowans,” said Shipley. “And I just want to stand up in support of Senator Dawson’s bill to try and close some of these loopholes that even I could figure out were coming.” Following Gov. Reynolds’ approval, many others welcomed the new regulations. “This has created a lot of awareness about these products, and it’s put things in place that were necessary,” said Alec Travis, owner of the Iowa-based brewery Field Day Brewing, which offers THC-infused beverages. “Having a small cap while people get used to these products is probably good.” Earlier in February, House Study Bill 665 was introduced, which would give the Iowa Department of Health and Human Services the ability to regulate consumable hemp products. “We thought we were dealing with the intoxicating aspect, only to find out that there are ways to get around that,” said Rep. Steve Holt. “So it’s sort of the wild, wild west out there in a lot of ways, with THC-infused drinks being able to be served to minors, a lot of other things going on that are not acceptable.” The bill has not received any further hearings after February 19.  Similar hemp regulations are also being pursued by other states, such as Georgia. Earlier this month, Gov. Brian Kemp signed Senate Bill 494, which “makes changes to the framework for hemp regulation in Georgia to allow the Georgia Department of Agriculture to have greater oversight and enforcement power and adds labeling, packaging, and marketing requirements to protect children from misleading and dangerous marketing.”  At the signing ceremony, Kemp explained that hemp cultivation is rapidly growing. “The vast majority of the jobs and the vast majority of the investment that have been created by these great private-sector companies … have been located outside the metro-Atlanta counties, creating opportunities for Georgians to succeed no matter what their zip code,” Kemp said. Additionally, Kemp signed Senate Bill 420 as well, which prevents a “foreign adversary” from owning agricultural land. “As valued members of our state’s number one industry, Georgia’s farming families deserve our enduring support as they face unprecedented challenges, including having to navigate disastrous federal energy policies, attempts by foreign adversaries to acquire farm land, and theft of property,” Kemp said. “We are tackling these challenges head on, and I want to thank our legislative partners for their work on these important issues.” On May 17, GOP House representatives recently published a 942-page draft version of the 2024 Farm Bill. Although still a work in progress, the draft currently includes a revision of the word “hemp” and provides numerous separate categories to label cultivators growing hemp for the purposes of animal feed, fiber, or non-food-based production of grain, seed, or oil.

https://hightimes.com/

Research Shows Evidence of Methylphenidate Provoking Relapse in Former Cocaine Users

In a study that was originally published late last year, researchers unveiled the risks for former cocaine users who may relapse by taking methylphenidate. Methylphenidate is used as a treatment for attention-deficit hyperactivity disorder (ADHD), and is often recognized through brands such as Aptensio XR, Concerta/Concerta XR-ODT, Jornay PM, and most commonly, Ritalin. As a stimulant drug, these medicines increase brain neurotransmitters such as dopamine and norepinephrine, to help a patient achieve better focus and behavior control. To a lesser degree, methylphenidate can also be used to treat narcolepsy as well. Methylphenidate is currently a Schedule III substance in the U.S., and has a history of misuse. According to Psypost.org, college students sometimes use methylphenidate to help them focus. Although methylphenidate has shown some promise in studies as a treatment to help people abusing cocaine, it comes with a few concerning side effects such as cravings and relapse. Researchers also found that methylphenidate use in conjunction with fluoxetine (a treatment for depression) actually mirrors the effects of cocaine. The study entitled “Methylphenidate with or without fluoxetine triggers reinstatement of cocaine seeking behavior in rats,” was originally published in the December 2023 issue of Neuropsychopharmacology, and lead by researchers Lorissa Lamoureux, Joel Beverly, Heinz Steiner, and Michela Marinelli. Study author Michela “Micky” Marinelli works at the University of Texas as an associate professor, and explained the history behind this unique study topic. “The interest started many years ago, from a creative graduate student I worked with in Dr. Frank White’s lab: Cindy Brandon. Cindy had school-aged children and noticed that more and more children at school were being diagnosed with ADHD and treated with methylphenidate,” Marinelli explained. “She wondered if this could pose a risk to develop stimulant addiction and she set out to study this in rodent models. She found that rats are not likely to self-administer very low doses of cocaine (they are too low to have an effect) but they will self-administer these low doses of cocaine if they have been previously exposed to methylphenidate (Brandon et al., 2001). She continued this line of research as a postdoctoral fellow in Dr. Heinz Steiner’s lab. Dr. Steiner was an expert in studying gene expression and together they found that methylphenidate alters gene expression in the brain in ways that were similar to cocaine, but not quite the same.” She added that according to Dr. Steiner’s research, methylphenidate elevates just dopamine and norepinephrine in the brain, but cocaine elevates those two as well as serotonin. Because of these similarities. “So he asked: what would happen if people taking methylphenidate also take antidepressant drugs like selective serotonin-reuptake inhibitors (SSRIs), which elevate serotonin. Would the methylphenidate + SSRI combination become cocaine-like?” Dr. Steiner observed gene expressions in the brain, which revealed the answer to his questions. Together, Dr. Stein and Marinelli wrote a grant study revealing the risks of using both a methylphenidate and an SSRI. “At this point in time, methylphenidate started to be taken not just in the clinic, as a medication for ADHD but also recreationally or as a ‘cognitive enhancer’ so we set out to examine both low and high doses of methylphenidate, to mimic (as much as possible in a rat) doses used in the clinic (low doses) vs. those used recreationally or as a cognitive enhancer (high doses),” Marinelli explained. In the most recent study, researchers studied male Sprague Dawley rats in a controlled setting. Rats were trained to self-administer cocaine as a way to mimic youth cocaine use. This was followed by a withdrawal phase when cocaine access was removed, where rats exhibited “cocaine-seeking behavior,” which included “nose poking” whenever they would receive the cocaine. Then an extinction phase followed, where the rats would learn to no longer exhibit that behavior. The next step included giving the rats either a high dose of methylphenidate or a combined dose of methylphenidate and fluoxetine to see if the rats would relapse and begin exhibiting cocaine-seeking behavior once again. “One needs caution extrapolating studies in rodents to human,” Marinelli said to PsyPost in an interview. “But at least in rats, if one has previously taken cocaine, taking methylphenidate can push that individual (rat) to seek cocaine again. This happens at high doses of methylphenidate, comparable to those used recreationally or as a cognitive enhancer.” Researchers also observed that there was no significant difference between rats who took methylphenidate alone, or the combined methylphenidate with fluoxetine, showing that fluoxetine doesn’t impact the effect. “We were surprised that adding a SSRI (fluoxetine) to methylphenidate did not exacerbate the effects of methylphenidate,” said Marinelli. “The effects we saw were due to methylphenidate alone.” It’s easier to study rats in an isolated, controlled environment versus studying humans, which leaves much to be desired in human observations. “It will be important to examine how much this work translates to human populations,” said Marinelli. “These are difficult to study as, unlike rats, they are not in a controlled environment, where we can determine the dose, duration, and manner in which they are exposed to different drugs or medications or treatments.” The rats also did not have ADHD, which could lead to different results in a human trial. “When I teach about addiction in summer camps or to undergraduate students, I ask how many of them know of someone who has taken methylphenidate as a cognitive enhancer. Almost all raise their hand. When I then ask them if any of them have, nobody raises their hand—so self-reported use of methylphenidate might be difficult to obtain. Anonymous questionnaires are helpful, but not if one wants to obtain more information from a person, which is only done face-to-face.”

https://hightimes.com/

Fentanyl Dealer on Snapchat Who Caused Deadly Overdoses Gets 20 Years in Federal Prison

A man who used Snapchat to sell fake oxycodone pills that actually contained fentanyl—leading to the death of a teenage girl as well as several other overdoses—faces 20 years in prison. Jeremial Lee Leach, 20, of Evansville, Indiana, has been sentenced to 20 years in federal prison, followed by five years of supervised release, after pleading guilty to one count of Distribution of Fentanyl Resulting in Death, one count of distribution of fentanyl, and one count of distribution of fentanyl resulting in serious bodily injury. Michael Gannon, Assistant Special Agent in Charge of U.S. Drug Enforcement Administration-Indianapolis, and U.S. Attorney Zachary A. Myers for the Southern District of Indiana released an announcement on May 17 describing the ordeal and the consequences. Leach sold fentanyl on Snapchat as “Mel,” resulting in at least three overdoses, one of which resulted in the death of a 19-year-old woman. “Mel” sold small blue pills marked with M 30 which is supposed to indicate they contain oxycodone hydrochloride—i.e. sold as Oxycontin, Reltebon, Zomestine, etc. Researchers call fake M 30 pills as “Dirty 30s,” and they’re highly dangerous—the slightest miscalculation of fentanyl can easily stop breathing. “This young woman should be alive today. Mr. Leach pushed deadly poison over social media, ending a teenager’s life far too early, and risking many more,” said U.S. Attorney Myers. “Fentanyl traffickers commit their crimes with utter disregard for the lives of our friends and neighbors or the harm they cause to families in our community. I commend the outstanding work of the DEA, the Evansville Police Department, the Evansville-Vanderburgh County Drug Task Force, and our federal prosecutors to secure some measure of justice for the victims of this fentanyl dealer. The sentence imposed here should serve as a warning: these poisons kill—and selling them will earn you decades in federal prison.” On June 25, 2022, in the late hours of the night, officers with the Evansville Police Department (EPD) responded to a call about an overdose from a residence on Wedeking Avenue. The first woman was lucky—and responders were able to revive her with naloxone.  But within hours, at approximately 10:55 a.m. the next morning, EPD officers responded to the same residence for the overdose of another woman, who was only 19 years old, who subsequently died. The coroner found a fake oxycodone pill containing fentanyl when examining the body. The cause of both overdoses was determined to be fentanyl intoxication. But “Mel” on Snapchat wasn’t done dealing his fake oxycodone pills. On Aug. 20, 2022, EPD officers were dispatched to a restaurant located on Hirschland Road concerning an overdose. There, the officers found a woman hunched over, falling out of consciousness. But she was also lucky and was revived with naloxone and the woman regained consciousness. The woman told police that she thought she had simply taken a 30 mg tablet of oxycodone, which would not have caused an overdose. The woman’s companion, identified as “Leach,” supplied the pill at a residence on Shanklin Avenue. It was again traced to “Mel” after officers with the Evansville-Vanderburgh County Drug Task Force set up two more drug deals a few months later. Police then executed a search warrant at Leach’s residence on Shanklin Avenue, where officers found 33 blue pills marked “30,” a digital scale, two 9mm pistols, and approximately $1,843 in cash. “The sentence imposed on Mr. Leach is righteous and justified. Mr. Leach utilized social media platforms to advertise the sale of fentanyl and continued distributing the poisonous fentanyl even though it had already caused fatal and near fatal overdoses. The DEA would like to extend their deepest condolences to the Duncan family and all families who have lost a loved one to a fentanyl poising,” said DEA ASAC Gannon. “DEA remains committed to working hand in hand with our state, local and federal partners in order to keep our communities safe.  DEA commends the outstanding work by the Evansville Police Department, The Evansville-Vanderburgh County Drug Task Force and the United States Attorney’s Office.” A much lesser “threat” on Snapchat is the sale of weed. A woman was busted in 2018 for setting up her weed business on Snapchat (which is admittedly much safer than selling fentanyl.) The Beatrice Daily Sun reported in 2018 that Nebraska authorities were tipped off about a Snapchat video made by a woman named Madison D. Carlson. In the video, she held a large bag of cannabis, with a corresponding caption reading “Hit me up.” Following the post, someone snitched, and authorities went to Carlson’s residence around 9:30 p.m. and immediately noticed two cars in a nearby alley with their lights on. In one vehicle, police found Carson with one female minor. According to police documents, the car reeked of weed. In the other, a male juvenile, who, upon further inspection, was carrying a concealed bag of marijuana in his waistband. The two female accomplices told police they had just gotten rid of the pot until Carlson was removed from the vehicle, and eventually forked over an additional 32 grams and $80 in cash. Since minors were involved, Carlson also faced serious charges, even though cannabis is not capable of causing bodily injury in the same way that fentanyl is. Plugs can be found on just about any social media platform, but especially when it comes to pills, buyer beware, as deadly counterfeit pills abound.

https://hightimes.com/

Study: Cannabis Use Associated with ‘Marginal Increase’ in Light Physical Activity

As modern-day cannabis research persists, studies have increasingly shed light on prevailing stereotypes of cannabis users, those persistent attitudes that cannabis makes people lazy and unmotivated.  Given the increased accessibility of cannabis in the United States and beyond, it’s now clear that there is no fixed demographic when it comes to cannabis use. The research shows it, too, regularly concluding that cannabis may actually fit in nicely with those pursuing a more active lifestyle. One of the most recent studies to examine this relationship was published last week in the journal Cannabis and Cannabinoid Research, measuring the physical activity and sedentary behavior among young-to-midlife adults and confirming that cannabis use is actually associated with a marginal increase in daily light physical activity (LPA). Researchers used data from the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2014 to investigate the relationship between cannabis and physical activity.  The study included U.S. adults aged 18 to 59 who responded to the questionnaire and had at least four days of activity data using wrist-worn accelerometers to track physical activity. The findings drew data from 4,666 adults, 658 (14.1%) of which reported cannabis use within the past 30 days. Researchers said that it is “the largest cohort in which the relationship between cannabis use and physical activity has been studied.” The accelerometer data found few differences in sleep or physical activity between people who did and did not use cannabis over the past month. While there were also no differences found between groups in daily moderate-to-vigorous physical activity (MVPA) time, daily time spent doing LPA was higher among recent cannabis users. However, the difference is minimal, as those who used cannabis in the past month had 102 minutes of light physical activity per day versus 99 minutes for those without past-month cannabis use. “With the rising prevalence of cannabis use, there have been concerns of its potential effects on physical activity levels,” the study concludes. “In this population level-analysis, recent cannabis use was not independently associated with daily sedentary time or MVPA, and it was associated with a marginally greater daily LPA time of unclear clinical significance.” Researchers noted that more than half of the participants were 18-29 years old, “which may suggest selection bias toward younger and healthier people in the NHANES sample” and may not be a representative sample of the general adult population.  The study also did not explore motivations surrounding cannabis use, though researchers noted the reasons could include exercise, pain, anxiety or sleep. The study also did not include data surrounding frequency of consumption or specific products used. Authors said that further reason could be useful to examine whether the findings were generalizable to specific subgroups who use cannabis for chronic or neuropathic pain. “Our findings provide evidence against existing concerns that cannabis use independently promotes sedentary behavior and decreases physical activity,” authors concluded, highlighting that the longstanding “lazy stoner” archetype often portrayed with chronic cannabis users “does not acknowledge the diverse uses of cannabis today.” It’s one of several recent students examining cannabis use and physical activity, similarly showing that these tired attitudes surrounding cannabis consumers may need to be examined in a new way in regard to today’s modern cannabis community and broad user base. A study published last month found that regular cannabis consumption was associated with more positive emotions and fewer negative emotions, alongside minimal effects of motivation or objective effort willingness. “When frequent cannabis users get high, in other words, they are no more apathetic, nor less extrinsically or intrinsically motivated to pursue their goals,” researchers said. “They are, however, slightly less motivated to do things when they are high because they would be upset with themselves if they did not do them.” Other research has honed in on cannabis use and physical activity specifically.  Another study from earlier this year showed that cannabis users take more walks on average compared to non-users and e-cigarette users and that they are no less likely to engage in basic exercise and strength training compared to non-users.  A similar study looking specifically at Americans 60 and older found that this demographic of cannabis consumers exercise more than their non-cannabis-consuming counterparts, while another study found that cannabis is increasingly being used in conjunction with exercise and may increase positive mood and enjoyment during workouts.

https://hightimes.com/

High Five: 5 Cultivation Styles

Using aeroponics, cannabis roots are suspended in the air and are fed water and nutrients via a fine mist. Aeroponics doesn’t require any type of medium or substrate, and the growing style is commonly used to develop clones. This is done through the use of cloners, or mini aeroponic systems that blow a mist over clones to allow growth. The lack of a medium usually ends up meaning less space per plant, and the roots don’t have to fight for space. One of the cons to aeroponic growing is that when the pumps break down, the roots die quickly without an alarm and a fast response. Since growers are dependent on timers, valves, and pumps working properly, there are plenty of ways to mess up the system if you don’t know what you’re doing. This relatively rare method combines aquaculture—small fish, crayfish, prawns, or snails—with hydroponics, feeding the plants with natural nutrients produced by aquatic animals instead of synthetic nutrients. The main reason growers experiment with aquaponics is for sustainability and eco-friendly purposes. It abandons any reliance on fertilizers that are mined and manufactured, so you can be sure no synthetic fertilizers end up in the final, chemical-free product. Online, some people say aquaponics is a complicated, overhyped process with few rewards, while others praise the benefits. Hydroponic cultivation is the process of growing plants in a water-based nutrient solution that doesn’t use soil. Roots are grown in substrates like vermiculite or perlite (porous minerals), as well as coco coir (coconut husk fiber). They absorb water and nutrients like a sponge and roots grow around them. Hydroponics ideally provides a more controlled grow site, promoting faster growth, potentially higher yields, and higher nutrient uptake. Growers often take drastic measures to ensure their hydro setup is sterile, and they have to deal with pesticides less often.  The Sea of Green (SOG) growing technique is designed to maximize the yield per square foot of a grow operation by growing lots of small cannabis plants rather than fewer larger ones. It creates a dense canopy that can be harvested earlier with the plants growing a single large bud instead of branching out. A variation, the Screen of Green (SCROG) method, utilizes horizontal netting to create uniformity. SOG and SCROG setups are typically created by commercial operations that deal with larger-scale grows. These ways can be maximized through super cropping and other pruning and suspension techniques. Keep it natural, the way nature intended, by growing plants in soil. Generally speaking, it’s easier to maintain a plant grown in soil than in most growing methods and it’s a great medium for beginners. Soil is also an abundant source found everywhere, while quality varies. Living soil, a variation of this technique, is when the soil contains organic matter, minerals, water, air, and microorganisms that work together synergistically. Cultivating in living soil is believed to maximize the terpene and flavor profiles of plants. This article was originally published in the April 2024 issue of High Times Magazine.

https://hightimes.com/

Marital Status Uniquely Affects Psychedelic Experiences, Study Shows

As it turns out, your marital status could affect the extent to which psychedelics can lower your stress levels. And it appears that single folk may experience the greatest benefit of psychedelics.  An analysis of data from the National Survey of Drug Use and Health revealed that individuals who had used psychedelics at least once in their lives, in general, had lower levels of psychological distress, according to research PLOS ONE. This association was most pronounced among people who were single and significantly weaker among those who were married, widowed, or divorced, PsyPost reports.  There’s already loads of research that clearly establishes a positive correlation between psychedelics and mental health. The Department of Veteran Affairs is funding research into psilocybin and MDMA to treat PTSD and depression. The FDA recently recognized LSD’s potential to treat anxiety. And there’s a study suggesting that DMT may be an effective treatment for depression. The research into the martial status and tripping looked at classical psychedelics like LSD, psilocybin, mescaline, and DMT, in addition to MDMA.  The study’s author, Sean M. Viña, sought to explore the relationship between psychedelic use, marital status, household size, and psychological distress. He hypothesized that married individuals who have used psychedelics might experience reduced distress and that those in larger households would face increased distress. He also suspected that the beneficial effects of psychedelics on distress would be least pronounced among people with large households.   Viña analyzed data from the National Survey of Drug Use and Health, which is an annual survey conducted across all 50 U.S. states and the District of Columbia. This survey seeks to measure the pervasiveness of substance use and mental health issues in the United States.  This analysis looked at data on people’s distress levels over the past month using the Kessler Psychological Distress Scale. The Kessler Psychological Distress Scale (K10) is a straightforward tool for measuring psychological distress. It consists of 10 questions about emotional states, each with five possible responses. The K10 can be used as an easy screening method to figure out one’s levels of distress (you can try it here).  It also considered whether participants had ever used classic psychedelics like DMT, ayahuasca, psilocybin, LSD, mescaline, peyote, or MDMA. It also included information regarding participants’ marital status, household size, and other demographic details. While single people won in some ways, and we’ll get to that, the results indicated that married individuals experienced lower levels of distress compared to single and divorced people. Married folks’ distress levels were actually comparable to widowed individuals.  Interestingly, the divorced individuals had the highest levels of drug use, unrelated to the psychedelics, which included cannabis but also tobacco, cocaine, tranquilizers, inhalants, pain relievers, and heroin. They also were more likely to have started drinking at an earlier age. While some of that substance use could be in reaction to divorce, it also may indicate that, unsurprisingly, an unhealthy relationship with drugs could lead to relationship problems.  Those who reported using classic psychedelics, in general, had generally less psychological distress. This was held true even after considering marital status and household size. But the connection between psychedelic use and reduced distress was strongest in single individuals. It was also significantly weaker in those who were married, widowed, or divorced. So, while being partnered or mourning a partner could lead to less stress in general, such folks may have a reduced benefit from taking psychedelics.  Notably, and giving child-free people a reason to celebrate, those with the most stress had larger households. If a person using classic psychedelics was married, the connection between living in a large household and experiencing psychological distress was even stronger.  “The results confirm the predictions that LCPU [lifetime classic psychedelic use] exacerbates the negative consequences of household size for the heads of households who are married, widowed, and divorced. The results also suggest that larger households are associated with harm regardless of marital status, but the negative consequences decrease for single psychedelic users as the household size increases,” Viña explained.  Viña went on to conclude that: “Widowed psychedelic users may experience some benefits from living with more people, but these benefits decrease as the household size becomes too large. In contrast, among married or divorced psychedelic users, the distress caused by household size worsens as the family sizes increase. Finally, for widowed psychedelic users, there is a negative association between household size and distress, but this association decreases at a decreasing rate.” So, while, if you’re windowed, it might not be a bad idea to move in with a friend, don’t move in with an entire family.  “These results can be explained by the increasing responsibilities that heads of households face as their families grow, which are then exacerbated by psychedelic use. On the other hand, single individuals may experience a diffusion of responsibility as their family sizes increase,” Viña said.  It’s important to remember that while studies like this are fascinating, we don’t always know if they’re demonstrating correlation or causation. In other words, while psychedelics could lead to less stress for single people, compared to overworked and exhausted moms and dads, on the other hand, it could just be that single people are more likely to have less stress and have a free weekend to spend tripping. 

https://hightimes.com/

Study: 87% of Festival-Goers Plan To Use Drugs, Cannabis Most Popular Choice

It’s the start of a new festival season, as music lovers far and wide prepare for a summer full of multi-day events featuring some of their favorite artists and DJs, along with plenty of dancing. For many, the festival experience also involves consuming a variety of drugs to amp up the experience. This year’s Drug Safety at Music Festivals study, conducted by research firm Innerbody, sheds additional light on the habits and plans of festival goers this year while also addressing some of the best ways for folks to stay safe should they decide to consume substances at these events. The study uses survey data from 900 people and suggests that about 87% of festival attendees plan to take drugs, a 10% increase from last year’s figure.  The study focuses on a variety of topics surrounding drug use at music festivals, beginning with the most popular substances that festival goers plan to use during the upcoming season.  Alcohol is always the top substance consumed at festivals, but the study did not include it and focused solely on drug usage. That said, cannabis takes the top slot by far, with 65.3% of festival goers who plan to use drugs saying they will consume cannabis. Authors note that the widespread legalization of recreational cannabis across the U.S. may make cannabis a less risky option for attendees.  Cocaine was the second most popular choice (46.5%), followed by psychedelics (26.1%), MDMA (19.4%), ketamine (19.3%), amphetamines (13.7%), opioids (12.1%), benzodiazepines (10.1%), synthetic drugs like bath salts or spice (9.7%), hallucinogens like salvia or peyote (6.1%) and inhalants (6%). Plans to use cocaine are up from last year’s numbers, though there was a 2% drop in the number of people who plan to use opioids — which authors noted as surprising given the continued opioid overdose epidemic though still “encouraging.” The study found that rock, hip-hop and EDM are the genres most likely to have audience members under the influence of drugs, with Wisconsin’s Rock Fest claiming the top slot as the festival with the most anticipated drug use, according to survey participants. The weeklong Burning Man festival held in Nevada’s Black Rock Desert took the second slot, while Coachella was third place for most anticipated drug use. The study also looked at drug concealment, consumption and testing behaviors among those planning to consume for festivals, finding that just 32.6% bring their own drugs with them to the event while the remaining 67.4% buy them at the festival. Last year’s results found that 46% planned to bring their own drugs to the events. Millennials were the most likely generation to buy drugs at the venue rather than purchasing them beforehand. In regard to drug testing, a majority (80.3%) test their drugs before the event or festival, an increase from last year’s approximately 67% figure.  “This increase in testing could be due to more awareness surrounding the U.S. opioid crisis and the public education efforts that have taken place,” authors note. “But while the data is encouraging, it still reflects the reality that 20% of festival goers could be taking potentially dangerous drugs at concerts.” Concealing drugs in backpacks and pockets are the most common choices, and researchers also found that attendees tend to take drugs in one of three places with a fairly balanced distribution: the restroom (29%), within the crowd (31%) or outside the festival gates (33%). Though authors indicate that the broader prevalence of drug testing is encouraging, the study notes that more than half of survey participants said they had experienced health-related issues that warranted medical attention while under the influence of drugs at festivals. The most common complications attendees experienced were heat stroke, a bad trip and dehydration.  The survey also found that drug use tended to lead festival goers to engage in riskier behavior at the events, with 66% of both Gen Z and millennial respondents reporting they had done so while attending festivals under the influence. Engaging in sex with a stranger was one of the most prevalent examples, most prominent among millennials, while one in every four millennials also reported “driving dangerously” after a festival ended. Authors note that abstaining and testing drugs before using them are some of the best harm reduction methods, though surveyed festival goers largely reported self-education about the drugs they were using, the risks and potential side effects as their go-to safety measure. The second-most common strategy was starting with a low dosage, followed by drug testing. “Being aware of your surroundings, remaining close to your friends, keeping hydrated, and familiarizing yourself with the location of medical tents are also easy and practical ways to help stay safe at music festivals,” authors close.

https://hightimes.com/

Adult-Use Cannabis Generates Over $20B in State Tax Revenue

Revenue generated by adult-use cannabis markets in the U.S. is showing its true impact on the economy. According to a report  by the Marijuana Policy Project (MPP) adult-use cannabis markets generated over $20 billion in tax revenue since launching in Colorado and Washington a decade ago. In November 2012, Colorado legalized marijuana for adults over age 21 by passing Amendment 64 to the Colorado Constitution. Washington state followed suit with a ballot initiative during the same month. Legal markets launched shortly after, and data on states that have implemented adult-use cannabis markets has been monitored by the MPP since 2014. “Legalizing cannabis for adults has been a wise investment,” the report reads. “Since 2014 when sales began in Colorado and Washington, legalization policies have provided states a new revenue stream to bolster budgets and fund important services and programs. Through the first quarter of 2024, states have reported a combined total of more than $20 billion in tax revenue from legal, adult-use cannabis sales. In 2023 alone, legalization states generated more than $4 billion in cannabis tax revenue from adult-use sales, which is the most revenue generated by cannabis sales in a single year. In addition to revenue generated for statewide budgets, cities, and towns have also generated hundreds of thousands of dollars in new revenue from local adult-use cannabis taxes.” The report goes through tax revenue collected in each individual state, noting the state markets that are not yet operational. Washington’s tax rate was among the highest in the nation, at a whopping 37% at retail with a 6.5% sales tax. “Twenty-four states have legalized cannabis possession for adults 21 and older. All but one of them—Virginia—have also legalized, regulated, and taxed cannabis sales. In two legalization states—Delaware and Ohio—sales have not begun yet.” The economic benefits that come from legalizing adult-use cannabis should be one of the movement’s greatest selling points, the report mentions. “It is important to note that the financial impact of legalizing and regulating cannabis for adult use is one of the many benefits of legalization,” the report concludes. “Adult-use cannabis legalization has also displaced the criminal market and freed up law enforcement resources to focus on serious crime. In legalization states, authorities actually know who is selling cannabis, where it is being sold, when, and to whom, because cannabis is produced and sold by legitimate, tax-paying businesses instead of drug cartels and criminals. Hundreds of thousands of individuals have been spared traumatic arrests, possible incarceration, and criminal records that shut the door of opportunity. Meanwhile, teenagers’ cannabis use rates haven’t increased, and voter support has grown.” The full report, “Cannabis Tax Revenue in States that Regulate Cannabis for Adult Use,” is available from MPP.  The data appears to align with tax revenue numbers released by the federal government, released in October 2023. The combined totals reveal that states with reported cannabis excise sales tax numbers totaled out to $5.7 billion since Q3 of 2021. A report published by the U.S. Census Bureau recently shows the progress of cannabis tax revenue numbers for each state. It’s the first report of its kind from the bureau and begins with the Q3 2021. “The Quarterly Summary of State and Local Government Tax Revenue provides quarterly estimates of state and local government tax revenue at a national level, as well as detailed tax revenue data for individual states,” the report explains. “The information contained in this survey is the most current information available on a nationwide basis for government tax collections.” It aligns with predictions the MPP released last year, according to a report on May 1, 2023 with data regarding cannabis tax revenue generated by states with legalization. Between 2014 and the end of 2022, the report shows that states had collected over $15.1 billion in tax revenue. Tax revenue from 2022 alone showed more than $3.77 billion collected, which was actually the first year that total state cannabis tax revenues decreased in comparison to 2021 with $3.86 billion. Even with seeing mature cannabis states collecting a decreased amount in cannabis tax revenue and newer states collecting an increased amount, MPP notes that the numbers are influenced by sales comparisons from the pandemic. The 2023 report also includes a year-by-year total of collected tax revenue as well. In 2014, tax revenue reached $68,503,980 and 2018 was the first year that cannabis tax revenue passed the million mark at $1,308,693,928.  MPP’s reports show the true potential that adult-use cannabis can bring, in the form of tax revenue.

https://hightimes.com/

MSO Stocks Soar After Biden Video Confirms Cannabis Is Moving to Schedule III

Cannabis stocks spiked immediately after President Joe Biden announced the reclassification of cannabis from a Schedule I to a Schedule III drug, endorsing the Justice Department’s recommendation.  Biden posted a video on X at 1 p.m. May 16, declaring that the U.S. Department of Justice would indeed reclassify cannabis, and within hours, cannabis-related stocks began rising amid the growing excitement. “Today’s step is another historic step moving forward,” Poseidon Investment Management co-founder Emily Paxhia told Yahoo! Finance on an episode of Market Domination. “I think anything around cannabis reform has been very difficult for the past 10 years plus, obviously, and so anything that’s working through an ordinary process and following the steps as it should is very confirmatory.”  Familiar names of bigger players in the industry are popping up. “We’ve seen increasing volumes in the top names in the industry,” Paxhia added. Multi-state operators (MSOs) would benefit the most from the Schedule III classification, like Canopy Growth, Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis, with operations in about three dozen states that allow cannabis sales. Shares of Canopy Growth, an enormous Canadian cannabis producer that trades on the New York Stock Exchange, rose 15%, to $11.95, after the tweet, Barron’s reports. The reclassification of cannabis doesn’t fix the gap between federal and state law, and it sparked some negative feedback of a potential pharmaceutical takeover. “On behalf of thousands of legal businesses operating across the country, we commend President Biden for taking this important first step toward a more rational marijuana policy,” said Aaron Smith, who heads the National Cannabis Industry Association. “Now it’s time for Congress to enact legislation that would protect our industry.” Forbes reports that shares of Canopy Growth Corp. ended up closing at roughly $11, an increase of over 11% on the day to a one-month high. Canadian cannabis producer Aurora Cannabis’ stock rose nearly 7%, closing Thursday at nearly $8 per share. Cannabis product manufacturer Green Thumb Industries’ stock rose nearly 3%, climbing to a high of just over $13. Shares of Trulieve Cannabis Corp rose as well to nearly 6% to just under $13 per share, while Tilray Brands’ shares increased by roughly 2.5% to just over $2 per share. Shares of Cronos Group also jumped over 4% on Thursday, closing at over $3 per share. It’s important to keep in perspective the overall picture. Despite the recent gains seen by cannabis MSOs, several cannabis-related stocks are far below their 5-year highs. Curaleaf is down nearly 66% from its February 2021 high, while Tilray is down nearly 97% from its high from the same month, Reuters reports. A 60-day commitment period will take place for a space for public input. The Justice Department will take comments on the proposal after it appears in the Federal Register. A final rule would have to be issued before the reclassification would take effect. The process can be lengthy,  and it must undergo a public comment period before it can be implemented, which can take up to a year. Part of the excitement surrounding the reclassification move could be centered on the probate changes in tax policy that is near. Legal advisors are expecting the limitations of tax code Section 280E will change significantly now that cannabis is moving to Schedule III of the Controlled Substances Act Duane Morris LLP & Affiliates, for instance, provided an explainer that indicates Section 280E provides that: “No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted.” Once cannabis is rescheduled as a Schedule III substance, Section 280E will not apply to that company’s tax return and additionally, the company would no longer be banned from deducting expenses on tax returns like any other type of legal business. Kilpatrick Townsend & Stockton LLP provided a Truth vs. Fiction article that explains  reclassification, in reality, it will probably take over a year for major changes to roll out. But one of the biggest lies or rumors, they explained, is that Schedule III will wipe out existing state cannabis markets. No one knows that at this point, and state cannabis markets have always operated in the gray market.

https://hightimes.com/

New Hampshire Senate Passes Cannabis Legalization Bill

Medical cannabis is legal in New Hampshire, but recreational use has only been decriminalized, not legalized. However, the New Hampshire Senate recently approved of a cannabis legalized bill in a 14-9 vote on May 16, and it’s the farthest that any cannabis legalization bill has reached to date. If passed into law, House Bill 1633-FN-A would legalize adult-use cannabis for those over 21 years of age, and establish a regulatory framework. This includes a possession allowance limit set at four ounces of cannabis, 10 grams of concentrates, and non-concentrate products up to 2,000 mg THC. Currently, the bill allows for 15 adult-use dispensaries to open up throughout the state in order to avoid market oversaturation. On May 16, Senators approved and rejected a variety of amendments. One change prevents cannabis business license owners from using their funds to lobby for cannabis legislation, and also bars those individuals from participating in “political activity” or contributing “funds to any entity engaged” in such activities. Another would present the question “Shall we allow the operation of cannabis establishments within the town or city?” to each municipality. A majority “yes” vote would permit retail outlets to open up, while a majority “no” vote would not permit stores to open, and the question cannot be asked again until three years have passed. Another amendment from Sen. President Jeb Bradley, which he described as his most important amendment, would be to change the proposal of an “advisory board” to that of a “cannabis control commission” in charge of approving rules and regulations. “If we’re going to protect public health, if we’re going to protect the kids in the state of New Hampshire, this board needs to be turned into a control commission,” said Bradley. “Everybody knows I don’t like this bill because of the public health implications. We can make it a little bit better with this amendment.” During the most recent hearing, Sen. Daryl Abbas explained that there is much more work to be done to flesh out the bill as it progresses. “No cannabis policy will be perfect,” said Abbas during the most recent hearing. He added that the current version of the bill “was drafted to balance the public safety needs of our communities with the legalization of cannabis.” Abbas added that previously there had been “some really, really, really scary policies” in the past, referring to one that would have permitted public smoking outside of the New Hampshire State House. New Hampshire polls reflect that a majority of residents approve of legalization. “Most of the polls are pretty straightforward, all well over 70 percent on this,” Abbas said. Sen. Bill Gannon was one legislator who opposed the bill, claiming that it would increase access to drugs throughout the state, making it more accessible to minors, and promote illegal sales. “We are going to change the fabric of New Hampshire if we pass this legislation,” Gannon said. Bradley also expressed his desire for the bill to be rejected by the Senate. “I don’t want to see it get out of the Senate, period,” he told WMUR. However, he admitted that he will do his best to amend the bill should it become law. “If there are 13 votes for it, I’m gonna try to make it the most user-friendly for New Hampshire,” said Bradley. “So keeping the black market out, making sure the regulatory process is tight, making sure that there is a THC limit on the products that can be sold, and making sure that big marijuana—you know, the same as Big Tobacco—is not dominating the politics of the statehouse. To me that’s really important if it’s going to pass.” Despite the opposition, advocates celebrated the news and potential future of cannabis in New Hampshire. Organizations such as Marijuana Policy Project praised the move on social media, but urged New Hampshirites to contact state senators and make their voices heard. Similar reactions were seen when the House approved the bill in April, such as Vicente LLP director of regulatory policy for cannabis and psychedelics, Jen Flanagan. “As with every other state that has legalized cannabis, New Hampshire must work out the details that work for their state and I hope the Senate takes this opportunity to see that safe and legal products are best for the public health and public safety of communities,” Flanagan said. Next up, House Bill 1633-FN-A will be heard in a second Senate committee, and later receive a second Senate floor vote, before it can be sent back to the House with the new amendments.  There is still the obstacle of getting the bill passed by New Hampshire Gov. Chris Sununu as well. Last May, Sununu explained his stance on cannabis legalization. “During my years as Governor, a bill to legalize marijuana in New Hampshire has never garnered enough bipartisan support to reach my desk. I have never vetoed legislation to legalize recreational marijuana,” he said in a press statement. “In 2017, I was proud to be the first Governor in New Hampshire history to sign legislation decriminalizing small amounts of marijuana so that no one would go to jail for simple possession. We expanded access to medical marijuana and provided a pathway to annul old convictions for marijuana possession.” Earlier this month, Sununu reiterated his criteria for signing a cannabis legalization bill. “I laid out the eight or 10 things that I’d like to see in that bill for it to get a signature on my desk,” he said in a WMUR interview. “If they meet those stipulations, I’ll sign it. If they don’t, I won’t.”

https://hightimes.com/

Psychedelics Task Force Bills Signed by Maryland Governor

On May 17, Maryland Gov. Wes Moore signed two bills that will create a psychedelic task force, called the “Task Force on Responsible Use of Natural Psychedelic Substances,” which was established by the passage of House Bill 548 and Senate Bill 1009. Effective starting on July 1, 2024, the two bills green light recruitment for the task force, which will consist of 17 members. Together they will research a variety of considerations for “natural psychedelic substances,” including psilocybin, psilocin, dimethyltryptamine (DMT), and mescaline (but not peyote). The task force’s mission is to recommend law and policy changes in order to build a program that “enables broad, equitable, and affordable access to psychedelic substances.” Task force members will also assess the best research available to better understand public benefits and uses of “natural psychedelic substances,” as well as review potential risks, and examine the best courses of action to increase accessibility.  Additionally, the task force is also required to study various barriers for healthcare practitioners and facilitators, such as insurance, licensing restrictions, zoning, advertising, as well as financial services. Members of the task force will also need to review how to approach civil penalty punishments for “the planting, cultivating, purchasing, transporting, distributing, or possessing of or other engagement with natural psychedelic substances.” The bills also address the requirement of expunging Maryland residents who were convicted of nonviolent psychedelic-related crimes, as well as releasing those serving time in prison for such crimes. The 17-member task force will include the following: a Senator representative, a House representative, the Secretary of Health (or Secretary’s designee), the Secretary of Disabilities (or a designee), the Secretary of Veterans Affairs (or a designee), the Director of the Maryland Cannabis Association (or a designee), a representative from either the University System of Maryland, Johns Hopkins University’s Center for Psychedelic and Consciousness Research, or Sheppard Pratt (a private, nonprofit healthcare provider), a representative from a Native American tribe with experience in religious and/or spiritual use of psychedelics, a behavioral health expert, a substance use disorder expert, a chronic pain treatment expert, a psychedelic-assisted psychotherapy expert, a psychedelic researcher, an expert regarding care in underserved communities, a drug policy reform expert, a law enforcement expert, a patient suffering from conditions in which psychedelics can help treat, and finally a physician who has experience with the “appropriate use” of psychedelic substances. The task force will be required to combine their findings in a report and sent to Moore and the general assembly no later than July 31, 2025. However, the task force will remain operating until December 31, 2026. HB-548 was introduced earlier this year in January, and passed in the House by March 13, with a final passing in the Senate by April 3, while SB-1009 followed suite with an introduction in February, followed by passage in the Senate on March 18 and House passage on April 2. While SB-1009 was still being considered in the Senate, sponsor Sen. Brian Feldman explained that cannabis has received its fair share of studies, and now it’s time to focus on the benefits fo other psychedelics. “This is actually an area that’s been studied far more than cannabis, whether for behavioral health issues related to post traumatic stress disorder, addiction broader behavioral health, depression issues, addiction, chronic pain, just another tool in the toolbox when you’re dealing with a treatments,” Feldman said in March, according to a WYPR news report. University of Baltimore, Maryland pharmaceutical studies professor, Andrew Coop, explained that there are numerous studies being conducted and show a lot of promise with psychedelic-assisted therapies. “There are 54 clinical trials currently going on in Maryland and again, with a safety profile, almost unheard of showing including no overdose, no withdrawal, no hangover and no addiction,” Coop said. “There are clinical trials funded by the National Institutes of Health. The Food and Drug Administration has designated psilocybin a breakthrough therapy. The Department of Defense is funding psychedelic research for veterans. This shows the support of the federal government and the safety profile.” Maryland legalized medical cannabis in 2013, while adult-use cannabis was approved by voters in November 2022, and sales began in summer 2023. Approximately 100 medical cannabis dispensaries were permitted to sell adult-use cannabis products at launch, and during the first week of recreational sales the state collected $20 million. The mainstream status of cannabis continues to grow, and it’s affecting more than just consumers. Maryland Law Enforcement officer applicants are currently required to abstain from cannabis use for three years before being considered, but in January Montgomery County Police Chief Marcus Jones stood up against that rule. “I think in today’s environment, where we are with the legalization of cannabis, that has now restricted law enforcement agencies, particularly larger agencies, across the state,” said Jones.In the meantime, Marylanders are already learning about the benefits of psychedelic-assisted therapy firsthand. Businesses such as Inner Path Wellness, based in Baltimore, Maryland, are offering an outlet to experiment with psychedelics as a treatment. Patient Tim Hamilton provided an oral testimony to the General Assembly on March 14 about the efficacy of such treatments. “They saved my life and it’s made me a better husband, a better father, and a better person,” Hamilton said. “It can help millions of people.”

https://hightimes.com/

The Real Sticky Icky Icky

Willie Nelson. Cypress Hill. Bob Marley. Aside from them, not many artists are more synonymous with cannabis than Snoop Dogg. Following his appearance on Dr. Dre’s 1992 single “Deep Cover,” the D-O-Double-G played a starring role on Dre’s debut solo album, The Chronic, which (in addition to the title itself) put their affinity for the sticky icky icky front and center. Not only was it marketed as a pack of rolling papers, it also contained track titles such as “The $20 Sack Pyramid” and “The Roach (The Chronic Outro).” Over the years, his connection to cannabis grew even stronger and in 1999, he and Dr. Dre teamed up again for 2001, the six-time platinum follow-up to The Chronic. With a green marijuana leaf tucked neatly into the right corner of the album cover, the weed theme continued with songs like “Let’s Get High” and Nate Dogg’s unforgettable hook, “Smoke weed every day-e-ay.” Snoop momentarily quit smoking once in 2002 and then again in 2005 when he started coaching a youth football league, but his hiatus didn’t last long. After about three months, he was ready to light up again. He’s been certified for medical cannabis in California to treat migraines since at least 2003, and in 2013, he claimed to be smoking approximately 80 blunts a day. Now, more than 10 years later, Snoop Dogg is intertwined with cannabis culture. Snoop’s loyalty to herb was tested in November 2023 when he tweeted out of nowhere, “After much consideration and a conversation with my family, I’ve decided to give up smoke. Please respect my privacy at this time.” People clutched their proverbial pearls in shock. Did hell freeze over? Is this a sick joke? Is Snoop OK? But, as many suspected, it was all a marketing ploy, and turned out to be a sales gimmick for a smokeless fire pit. After all, Snoop has become omnipresent in the world of advertising, endorsing everything from Corona beer and Tostitos to The General Insurance and Dunkin’ Donuts. His latest endeavor is a hemp-infused beverage called Do It Fluid, billed as an alternative to traditional smoking through “all-natural, high-quality ingredients that don’t sacrifice the high.” The line, created by the Hill Beverage Co., features THC and CBD infusions through four flavors in CBD-only and CBD and THC blends. “I’ve been in the cannabis game for decades, and I’m always looking out for revolutionary products,” Snoop Dogg says. “I love seeing new technologies and trends and being a driver of those. I always make time for things I’m passionate about, and two of those things happen to be weed and innovations.” For the uninitiated, Snoop Dogg began his career at Death Row Records and, in a full-circle moment, acquired the brand in 2022. Part of the restructuring included a new arm called Death Row Records Cannabis, which is ultimately how Snoop and Hill Beverage Co. formed a partnership. “My partner and head of operations, AK at Death Row Records Cannabis, connected me with Jake Hill and we started ideating flavors and ideas for a hemp-infused drink,” Snoop explains. “Beverages are ingrained into us humans as a familiar format of consumption, and I wanted to make sure as many people had access to Do It Fluid as possible, which is why we chose the hemp-derived delta-9 THC and CBD route.” To create the flavors, Snoop joined with Tiffany Chin, his head of cannabis and hemp operations, to come up with fruit punch and blue razz. “Jake’s team developed an amazing blood orange flavor that tied perfectly into the Death Row Records history,” Snoop says, alluding to former Death Row Records CEO Suge Knight’s association with the Piru Bloods gang. “Do It Fluid is just the start in my partnership with Hill Beverage Co. We’re looking to create more flavors, collaborations and product lines in the future to get to my fans and consumers, those who do and don’t know cannabis.” And Snoop knows cannabis. In 2015, he founded his own marijuana brand, Leafs By Snoop, but eventually shelved that brand for Death Row Cannabis, which became available in California last year and has since expanded to Michigan, with several more locations planned. AK, a longtime West Coast legacy cultivator, evidently has a flair for engineering tasty buds. But, of course, it’s much more than just business for Snoop—he’s a dedicated connoisseur. “I love the way it makes me feel and gets my creative juices flowing and how it bonds people in the creative world,” Snoop says of cannabis. “A lot of people enjoy smoking to listen to music and watch TV and movies. It just elevates the mind to a different place.” Right on cue, Snoop Dogg plugged his brand the moment he got the opportunity. When asked what a day in the life is like for him when it comes to smoking, he replied, “I wake in the morning, grab my Death Row Records Cannabis jar, unwrap a blunt, shake the guts out, and break the bud down with my fingers. After I smoke my blunt, I have another one ready for after my meetings and/or during rehearsals and recording. Death Row Records Cannabis has me stocked up on the best bud in California. It’s the only weed I smoke.” As Snoop Dogg’s business portfolio continues to expand, the 52-year-old has plans for incorporating a little self-care, too. “I have so many projects on deck and new products flooding all lanes and bringing more and more to my fans,” he says. “On a personal level, I’m also working on leading a healthier lifestyle, drinking more water, getting in the workout and eating better, eating right. 2024 is looking fantastic.” This article was originally published in the May 2024 issue of High Times Magazine.

https://hightimes.com/

The Library of Cannabis

Up in California’s Emerald Triangle, just north of Cal Poly Humboldt and nestled between the Mad River and a community forest, HendRx Farm is a commercial nursery dedicated to cataloging the community’s work with the cannabis plant. What started as a simple 400-square-foot operation now spans almost 10,000 square feet across multiple locations, keeping around 200 varieties of clones at a time in their catalog and serving farms across California. Together, Daniel Hendricks, Jeff Schirmann, and David Lunsford have built a resource where the preservation of plants is paramount. The calling at HendRx Farm is to create a viable source for farmers to secure not only the clones that are high value right now, but also the ones that helped put this whole game together, strains like Ringo’s Gift, Arcata Trainwreck, or Skunk #1. HendRx believes the mission to procure and hang onto these culturally-significant cultivars is not just a community service but a responsibility. Every sprout has a story to tell, and HendRx is helping to assemble the Criterion collection. I spoke with Hendricks while he was getting started on the clone selections for the next few growing cycles. “With an operation like this, juggling orders for so many farmers, you have to be seasonally minded,” he said. The company started in 2014, but for Hendricks, his days of growing can be traced back to the ’90s. Having grown up in Humboldt, he was attracted to cultivation and breeding early on, eventually finding companions who shared his enthusiasm for weed. Hendricks, Schirmann, and Lunsford bonded over the belief that a person has a right to farm, as well as a mutual thirst to learn the history of the cannabis strains that had proliferated throughout the West Coast. Together, the group became known for helping authenticate strains for growers. “We were good at validating if something was the real version of what you were after,” Hendricks said. In 2016, they chose to file as an official nursery after deciding it was not only what matched their shared passion but also what they felt the legal cannabis community needed most. Hendricks chuckled while describing their first setup. “It was this tiny little square box that was barely big enough for all of us and the plants,” he said. Today, they’ve developed that passion into a large-scale, thriving business that includes the launch of their genetic preservation library, where they authenticate, stabilize, and store cultivars that the community has deemed essential. Half of their main building is dedicated to this breeding project. The goal is to get up to 80 strains in the library, all independently bred, stabilized, and preserved through clones. Attaining this goal, Hendricks said, is in no small part thanks to their partner farms like SoHum Seeds and Hidden Prairie Farms, which grow these strains out and help them develop phenotypes for possible production. “We rely on them for so much, in terms of testing the product by growing and smoking it, but hearing their stories about how it grew, seeing all the effort and coordination from around the community, that’s undoubtedly the most fun part,” he said. It’s that feeling of community responsibility and respect that put HendRx in the unique position to preserve and become stewards of the famous CBD strain, Ringo’s Gift. Hendricks spoke about how this incredible story shows how the breeding and nursery community can work together to make sure something doesn’t disappear once the spotlight fades away. After cannabis breeder Lawrence Ringo’s passing in 2014, Hendricks was at a memorial service in Mendocino, where he heard Samantha Miller from Pure Analytics Lab talk about the first time they discovered the presence of CBD in Ringo’s Gift. She described how everyone on the call afterward was cheering and laughing and how inspired everyone felt. The HendRx team knew they had to hunt and find the seeds so they could, in some small way, do their part to honor this work. They worked tirelessly to find two variations of Ringo’s Gift, eventually called Katie’s Cut and Levi’s Cut. After a lot of calls and messages, they managed to procure a hemp-compliant clone hunted to help treat the mother of a local client named Katie. Then, with the aid of Purple Caper Seeds (creators of the Chocolate Hashberry), the HendRx team was able to get their hands on a cut that had been given to Purple Caper by Ringo’s son, Levi Lawrence, in a parking lot in San Jose, California years prior. This cut, now known as “Levi’s Cut,” was another key part of HendRx’s efforts. Armed with two versions of the plant, they went to work. Hendricks started making 1:1 hybrids while Schirmann began to stabilize it with a hemp variety, and then the calls started flooding in. People had heard about what they were doing and wanted to get their hands on this important medicinal strain to give to their friends. Among these calls were Levi and Danielle Lawrence, who then operated SoHum Seeds. After giving this strain back to Ringo’s family, to the very person who had handed over this cut in a parking lot years earlier, HendRx felt they had really achieved something important for the nursery community. Levi and Danielle Lawrence eventually chose Jerry Savage to operate SoHum Seeds to continue the Ringo’s Gift legacy, and Savage invited HendRx to be part of that mission. Today, HendRx manages facilities at SoHum Seeds in Whitethorn, California, where they operate an R&D section, along with garden space for Savage Farms. After successfully working with the Ringo’s Gift through breeding and experimentation, Hendricks figures they’ve successfully created at least 50,000 Ringo’s Gift plants over the last two years. “It’s definitely the most important clone we have, and it’s at the ethos of what HendRx does: preservation,” he said. When it comes to the concept of cannabis and legacy, Hendricks said that they prefer to use the term “heirloom” when referring to their work since it “better holds the reflection of what these strains are: plants with a rich position in history and a huge potential value to the future.” For them, these plants haven’t yet finished writing the legacy they will leave behind. Part of their daily mission is ensuring these heroic varieties make it to the final battle. To Hendricks, “legacy strains,” as the term pertains to retail cannabis, are too expensive to keep alive in today’s market, given the current profit margins. This makes preserving genetics paramount to ensuring we don’t lose what we already have, as people today are planting less of the classics like San Fernando Valley OG and newer strains like Lemon Cherry Gelato. “Preserving these strains ensures these plants don’t just leave behind a legacy, either because they stay valuable to the community or to the retail market,” Hendricks said. “It’s our duty to the community to preserve what the industry won’t save.” The Oxford English Dictionary definition of heirloom, in reference to plants, refers to a variety that is not associated with large-scale commercial agriculture. Hendricks referenced how the inherent value in these strains isn’t just in their flavor, historical importance, or medicinal value but also in the untapped intellectual property value the industry has left on the table. If a brand figures out how to adapt an heirloom strain for scalable cultivation and makes it a flagship product, especially one that’s part of their company mission to give back to cannabis, then that in and of itself is a valuable brand identity that’s empowered by that cultivar. In a way, that’s part of the work HendRx is doing, along with The Humboldt Legacy Project on the famous cannabis strain Skunk #1. After being procured by David Watson and preserved by Marty Yip of Sensational Solutions, HendRx was entrusted with the Skunk #1 to work with. Together with the Humboldt Legacy Project, they’ve already started testing something they’re calling the HLP Skunk #1 No. 1 or HLPS1. Currently, HendRx is in the second round of tester gardens grown through their partners in the project, MOCA Humboldt, which took home nine awards for their cannabis at the 2023 California State Fair. Hendricks remarked how together they are isolating possible production candidates like this HLP Skunk #1 No.1 but explained that the process is still a while away from a batch of clones being considered for retail because “some of these [plants] need commercial work and are perhaps unattainable under our current framework.” He went on to explain how the time and supplies required to grow a difficult heirloom strain, or something that takes 14 weeks or longer to finish up, often outweighs the possible return on investment, making them a harder sell during planting season. “Things like this require a big price tag in order to break even,” Hendricks said. “Growing a field of something like Trainwreck really needs subsidized farming.” Despite these concerns over sustainability in the current retail market, they were able to release a small amount from the first test garden to the public, including a survey created by HLP and HendRx that asks smokers for their feedback. Hendricks says the staff at MOCA Humboldt are all hyped about having this opportunity and someday being able to offer a product with an unbelievable history and proven provenance for smokers who want to try that old-school ’90s weed.  What does it take for a strain to end up in HendRx’s genetic preservation library? The answer to that is both simple and complex. “It has to pass the three wise men,” Hendricks said, meaning all three owners of the nursery have to look at each case and approve it, but there are a few factors that majorly contribute to the decision. Cost is an important factor. It takes around $1,200 a year to keep a single strain stored away. Hendricks admits that switching to tissue culture would be a smaller footprint for storing their library, but it would keep things further out of commercial rotation and increase wait times for their farm partners. Another big criteria is space, not just in terms of where to store plants but also how to store multiple cultivars together so that there’s a healthy ecosystem. Inside their Noah’s Ark, everything is operating in a sort of hibernation homeostasis, and there’s always a potential risk involved in bringing them out and back into storage. If a strain can prove itself to have a valuable history, be free of pathogens, and can do well in its storage facility and pass the test for all three owners, then it becomes part of the genetic preservation library. Hendricks made it clear that the library is about preserving older strains but that recent and current ones aren’t excluded from induction. “It has to be important, not just cool, and it has to have potential value in terms of research, rarity, terpene breakdown, market value, or education,” he said. He sees the mission as keeping these cultivars alive for the future, even more so than in the past. They recognize that the new heat and throwback strains from the ’90s might be more in demand than the hits of the ’70s, but that doesn’t mean those flavors don’t contain something super inspiring for the future. The whole thing is a lot like the preservation of music. There are more albums made in a day than you could listen to in a year, so deciding who and what gets preserved is a difficult task that requires a lot of dedication, research, and input from the community, along with a little bit of intuition sharpened by experience. One example he gave is Italian Icee, a strain that has gotten them a ton of positive feedback and is something they had a gut feeling about when it first landed in their hands. Hendricks explained that it was a rugged, sunbaked German man who approached them. He looked like a guitar tech or a roadie for some band your uncle loves and he said he had something special they needed to keep safe. He came back the next day with a tiny piece of paper that held a pile of seeds and the instructions for his Mason jar technique for germination; all hastily scrawled out like the recipe for a wizard’s potion. It was a gut feeling the guys at HendRx had that led them to keep it. After all, Ice Cream Cake crossed with Blueberry Muffin is nothing to necessarily write home about, but HendRx had a hunch, so they had Royal Lief grow it out and select the pheno: Ice Cream Cake x Blueberry Muffin #4. After that, it traveled to the R&D site at SoHum Seeds, where it languished for a year and a half before a client came asking for an Ice Cream Cake cross. Now, six years after getting that crumbled scrap of paper, Italian Icee has done quite well, a success Hendricks modestly attributes to the strain finding the right home for its story rather than the HendRx team’s gut instinct for sniffing out a winner. For every success story like this, there are a dozen or more heirloom cultivars waiting to find their voice in this evolving industry. I asked if any of these were becoming in demand with farmers last year in 2023, and Hendricks said that HendRx is getting a lot more requests from people wanting to try their hand at growing an heirloom strain, but producing orders on these cultivars takes a lot of time and labor so there are waitlists for many of the most recognizable names. “The longest lines are always for Trainwreck, Sour D, and Tangie,” Hendricks said. “But the lines for NF1, XJ13, and GSC are right at their heels.” Hendricks said his company likes to say the mission ends when you can find Sour D and Girl Scout Cookies in the garden department next to tomato starts and daffodils. The idea is that when they can create and maintain these strains for home gardeners and commercial growers alike, they no longer have to worry about these strains leaving enough of a legacy to be saved from extinction. Until then, HendRx will continue to expand the genetic preservation library to conserve and promote heirloom cannabis. This article was originally published in the May 2024 issue of High Times Magazine.

FAQ: How to use this hemp news hub

What topics does Chow420’s hemp news cover?

We aggregate and surface reputable coverage on hemp laws and enforcement, THC thresholds and policy proposals, cannabinoid products (CBD/Delta-8/hemp-derived THC), compliance, lab testing, recalls, and broader industry news.

Is this legal advice?

No. This page is for news and education. Hemp rules can change quickly and vary by state—always verify against the latest official guidance and consult qualified counsel for compliance decisions.

How do I evaluate hemp product safety claims?

Look for current third‑party COAs (Certificates of Analysis), clear ingredient labeling, and transparent sourcing. Be cautious with vague potency claims or missing lab reports.

Why do some articles mention Delta‑8 or “hemp-derived THC”?

These products often sit at the center of policy and enforcement changes. We track major updates so shoppers and brands can understand evolving requirements and market impacts.

How often is the news updated?

The crawler is scheduled to run daily. New items appear as sources publish updates.